Corvus Pharmaceuticals, Inc. (CRVS)
Automate Your Wheel Strategy on CRVS
With Tiblio's Option Bot, you can configure your own wheel strategy including CRVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CRVS
- Rev/Share 0.0
- Book/Share 0.6839
- PB 5.5274
- Debt/Equity 0.0234
- CurrentRatio 4.9026
- ROIC -0.6184
- MktCap 291493188.0
- FreeCF/Share -0.3961
- PFCF -10.2042
- PE -6.5856
- Debt/Assets 0.0194
- DivYield 0
- ROE -1.1379
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CRVS | H.C. Wainwright | -- | Buy | -- | $11 | Jan. 2, 2025 |
News
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, Investor Relations Leiv Lea - Chief Financial Officer Richard Miller - Chief Executive Officer Conference Call Participants Aydin Huseynov - Ladenburg Graig Suvannavejh - Mizuho Securities Li Watsek - Cantor Jeff Jones - Oppenheimer Roger Song - Jefferies Sean Lee - H.C. Wainwright Operator Good afternoon, everyone.
Read More
Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials
Published: March 28, 2025 by: Seeking Alpha
Sentiment: Positive
Corvus Pharmaceuticals' leading drug candidate is Soquelitinib, which has broad potential across PTCL, atopic dermatitis, and ALPS. Unfortunately, it seems Corvus' early AD data might have disappointed investors (at least initially). Still, Soquelitinib's promising Phase 3 PTCL trial results are due late 2026. Its PFS metrics might help it to differentiate from other standard chemotherapy treatments.
Read More
Corvus Pharmaceuticals: Now At Cruising Altitude
Published: March 28, 2025 by: Seeking Alpha
Sentiment: Positive
Corvus Pharmaceuticals' stock has experienced volatility due to mixed clinical data, particularly from their lead asset soquelitinib's Phase 1 trial in atopic dermatitis. The company has promising developments, including a Phase 2 trial for autoimmune lymphoproliferative syndrome and potential solid tumor trials, but current data is inconclusive. Significant shareholder activity, including warrant exercises, has impacted stock price and ownership dynamics, with potential future dilution if more shares are issued.
Read More
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript
Published: March 25, 2025 by: Seeking Alpha
Sentiment: Neutral
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q4 2024 Earnings Conference Call March 25, 2025 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Leiv Lea - CFO Richard Miller - CEO Conference Call Participants Jeff Jones - Oppenheimer Aydin Huseynov - Ladenburg Thalmann Cha Cha Yang - Jefferies Daniel Bronder - Cantor Sean Lee - H.C. Wainwright Operator Good afternoon, everyone.
Read More
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum
Read More
About Corvus Pharmaceuticals, Inc. (CRVS)
- IPO Date 2016-03-23
- Website https://www.corvuspharma.com
- Industry Biotechnology
- CEO Dr. Richard A. Miller M.D.
- Employees 31